Cheplapharm to acquire 20 medicines and three Sanofi sites

M&A · PartnershipCorporate Action
โดย Pharmaceutical Technology·FR·Read original
Summary · why it matters

Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi. Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm, expanding on a working relationship between the two companies that began in 2014. The selected medicines, including Lovenox/Clexane (enoxaparin), are intended to benefit from Cheplapharm's operational approach, and the companies stated that different operating models may better address the manufacturing, regulatory and commercial characteristics of established treatments compared to new medicines. Cheplapharm will acquire production sites located in Csanyikvölgy in Hungary, Jurong in Singapore, and Ploërmel in France, which employ approximately 400, 100, and 65 employees, respectively, with existing employment terms and collective agreements expected to remain in place. The planned commercial transition is targeted to begin in the first quarter of 2027, with full completion anticipated by the third quarter of 2027, subject to regulatory approvals and employee consultations, and the transaction is not expected to affect Sanofi's financial guidance for 2026.

Impact on stocks 1

Health Care▲ · 1 stocks
Sanofi SA
SAN
± MixedCapitalrelevance

Sanofi divests 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4% equity stake, a portfolio restructuring with no stated impact on 2026 guidance.

Off-coverage companies 1

Cheplapharm Arzneimittel GmbHPrivate▲ Positive
Capitalrelevance

Cheplapharm acquires a portfolio of 20 mature medicines plus three manufacturing sites from Sanofi, expanding its established-medicines business.

© 2026 MarketDXNews